What is Syndax Pharmaceuticals's market cap?

Syndax Pharmaceuticals (SNDX) has a market capitalization of $1.9B and trades on NASDAQ.

What is Syndax Pharmaceuticals's revenue and profitability?

Syndax Pharmaceuticals generated $217.4M in trailing twelve-month revenue with a net loss of $243.2M, representing a net margin of -111.9%. These figures are based on the Q1 2026 filing.

Who are Syndax Pharmaceuticals's competitors?

Syndax Pharmaceuticals's key competitors include Incyte, Kura Oncology, Biogen, and others. These companies compete in similar markets and product categories.

Who does Syndax Pharmaceuticals partner with?

Syndax Pharmaceuticals's notable partners include Incyte, Royalty Pharma, Eddingpharm, and others.

What subsidiaries does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals's subsidiaries include Syndax Pharmaceuticals Netherlands B.V..

Where is Syndax Pharmaceuticals headquartered?

Syndax Pharmaceuticals is headquartered in United States of America and employs approximately 184 people. It has been publicly traded since 2016.

Syndax Pharmaceuticals

SNDX

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing a pipeline of first-in-class cancer therapies.

Market cap

$1.88B+119%

Revenue$217.4M+397%

Net income-$243.2M+26.6%

EPS (diluted)-$2.79+27.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$64.9MMiss by $4.9M EPS-$0.48Beat by $0.11

Read the full report

Next report

Aug 3, 2026 (In 6 days)

Revenue estimate$79.4M

EPS estimate-$0.45

Financials

Q1 2026

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

Valuation & ratios

Valuation

See full

Market cap$1.88B+119%

Enterprise value$2.1B+94.0%

P/S8.6×-2.3×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Competitors

By market cap

AbbVie$453.92B+34.7%

Biogen$29.6B+52.5%

Incyte$23.3B+70.9%

Arcus Biosciences$3.7B+258%

Syndax Pharmaceuticals$1.9B+119%

Kura Oncology$927.7M+65.6%

Verastem$543.1M+86.8%

CTO

Citius Oncology, Inc.$53.8M-64.8%

By revenue growth

Syndax Pharmaceuticals+397%

Arcus Biosciences+67.4%

By net margin

Incyte26.71%+26.2pp

Biogen14.3%-0.8pp

AbbVie5.79%-1.5pp

Syndax Pharmaceuticals-111.88%+646pp

Arcus Biosciences-156.36%+121pp

Kura Oncology-411.19%-77.6pp

Profile

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing a pipeline of first-in-class cancer therapies. The company leverages strategic partnerships and in-licensing to advance treatments for high-unmet-need conditions, including acute leukemias and chronic graft-versus-host disease. Its core value proposition lies in its ability to bring novel targeted inhibitors and monoclonal antibodies from clinical development to the oncology market.

Competitive position

Syndax holds a first-mover advantage with the first FDA-approved menin inhibitor and maintains a strong collaborative position through a significant co-commercialization agreement with Incyte.

GeographiesUnited States, China, Europe, Japan

Customer segmentsSpecialized Healthcare Providers, Patients

Business modelBiopharmaceutical R&D, Licensing and Royalties, Direct Sales

SuppliersContract Manufacturing Organizations (CMOs), Academic research institutions, Clinical trial cooperative groups, Raw material suppliers

CustomersSpecialty pharmacies, Hospitals, Government health programs (Medicare/Medicaid), Private health insurers

CountryUnited States of America

Listed2016

Employees184.0

CEOMichael A. Metzger

SectorHealthcare

IndustryBiotechnology

Websitesyndax.com

FilingsSEC EDGAR

Ask your AI about Syndax Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's market cap?: Syndax Pharmaceuticals (SNDX) has a market capitalization of $1.9B and trades on NASDAQ.
What is Syndax Pharmaceuticals's revenue and profitability?: Syndax Pharmaceuticals generated $217.4M in trailing twelve-month revenue with a net loss of $243.2M, representing a net margin of -111.9%. These figures are based on the Q1 2026 filing.
Who are Syndax Pharmaceuticals's competitors?: Syndax Pharmaceuticals's key competitors include Incyte, Kura Oncology, Biogen, and others. These companies compete in similar markets and product categories.
Who does Syndax Pharmaceuticals partner with?: Syndax Pharmaceuticals's notable partners include Incyte, Royalty Pharma, Eddingpharm, and others.
What subsidiaries does Syndax Pharmaceuticals have?: Syndax Pharmaceuticals's subsidiaries include Syndax Pharmaceuticals Netherlands B.V..
Where is Syndax Pharmaceuticals headquartered?: Syndax Pharmaceuticals is headquartered in United States of America and employs approximately 184 people. It has been publicly traded since 2016.